Merck, Hanmi sign $870M deal for NASH drug

BioPharma, biopharma nl, Daily, Efinopegdutide, Hanmi Pharmaceutical, Merck & Co, NASH, nonalcoholic steatohepatitis, Seoul, South Korea, SYN, Top Story / August 4, 2020

Hanmi will retain options for the drug, efinopegdutide, in Korea under the deal, in which Merck is paying the Seoul-based company $10 million upfront and up to $860 for development, regulatory and commercialization milestones.